罗善玉,纪宗红,张瑞霞

【摘 要】：非酒精性脂肪性肝炎（non-alcoholic steatohepatitis，NASH）是指肝组织病理学肝细胞脂肪变>5％、伴有炎症和肝细胞气球样变，伴或不伴肝纤维化。细胞焦亡是一种与炎症相关的新的程序性细胞死亡，细胞焦亡发生的关键是炎性小体的活化，而炎症反应的核心又是核苷酸结合寡聚化结构域样受体蛋白3（Nucleotide binding oligomerization domain like receptor protein3，NLRP3）炎症小体，因此NLRP3炎症小体与细胞焦亡的发生关系密切。NLRP3在肝脏疾病中发挥主要功能作用，现对NLRP3/caspase-1/1L-1β信号通路在非酒精性脂肪性肝炎肝细胞焦亡发生发展中作用机制做一综述，旨在为NASH潜在的治疗价值以及今后的研究方向提供参考。

【关键词】：NLRP3；炎症反应；NASH；细胞焦亡

[1] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases. Hepatology.2018.67(1):328-357. [2] Cusi K.Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis:pathophysiology and clinical implications. Gastroenterology.2012.142(4):711-725.e6. [3] 朱鹏,徐宗,王宇明.世界胃肠病学会全球指南:非酒精性脂肪性肝病及非酒精性脂肪性肝炎.临床肝胆病杂志.2014.30(09):842-845. [4] Younossi Z,Anstee QM,Marietti M,et al.Global burden of NAFLD and NASH:trends,predictions,risk factors and prevention.Nat Rev Gastroenterol Hepatol.2018.15(1):11-20. [5] 王允亮.葛根芩连汤及其有效组分干预非酒精性脂肪性肝炎PPARγ的作用机制研究,2014. [6] 郭亮,汤其群.非酒精性脂肪肝发病机制和治疗的研究进展.生命科学.2018.30(11):1165-1172. [7] Povsic M,Wong OY,Perry R,Bottomley J.A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis(NASH).Adv Ther.2019.36(7):1574-1594. [8] Sheka AC,Adeyi O,Thompson J,Hameed B,Crawford PA,Ikramuddin S.Nonalcoholic Steatohepatitis:A Review.JAMA.2020.323(12):1175-1183. [9] Csak T,Pillai A,Ganz M,et al.Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.Liver Int.2014.34(9):1402-13. [10] 周宗涛,邓利明,胡丽君,任强,张陆勇,李政.非酒精性脂肪肝药物治疗靶点及药物研究进展.中国新药杂志.2020.29(12):1363-1374. [11] Parthasarathy G,Revelo X,Malhi H.Pathogenesis of Nonalcoholic Steatohepatitis:An Overview.Hepatol Commun.2020.4(4):478-492. [12] Friedman SL,Neuschwander-Tetri BA,Rinella M,Sanyal AJ.Mechanisms of NAFLD development and therapeutic strategies.Nat Med.2018.24(7):908-922. [13] Yang W,Liu L,Wei Y,et al.Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH:a plausible role of adropin.Lab Invest.2021.101(3):369-380. [14] Loomba R,Friedman SL,Shulman GI.Mechanisms and disease consequences of nonalcoholic fatty liver disease.Cell.2021.184(10):2537-2564. [15] Guilherme A,Virbasius JV,Puri V,Czech MP.Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.Nat Rev Mol Cell Biol.2008.9(5):367-77. [16] 金芳,夏世文.NLRP3/caspase-1/IL-1β信号通路在缺氧缺血性脑损伤的作用.生命的化学.2023.43(01):16-22. [17] Jo EK,Kim JK,Shin DM,Sasakawa C.Molecular mechanisms regulating NLRP3 inflammasome activation.Cell Mol Immunol.2016.13(2):148-59. [18] Ramos-Tovar E,Muriel P.NLRP3 inflammasome in hepatic diseases:A pharmacological target.Biochem Pharmacol.2023.217:115861. [19] Hamarsheh S,Zeiser R.NLRP3 Inflammasome Activation in Cancer:A Double-Edged Sword.Front Immunol.2020.11:1444. [20] Broz P,Dixit VM.Inflammasomes:mechanism of assembly,regulation and signalling.Nat Rev Immunol.2016.16(7):407-20. [21] Dick MS,Sborgi L,Rühl S,Hiller S,Broz P.ASC filament formation serves as a signal amplification mechanism for inflammasomes.Nat Commun.2016.7:11929. [22] Zahid A,Li B,Kombe A,Jin T,Tao J.Pharmacological Inhibitors of the NLRP3 Inflammasome.Front Immunol.2019.10:2538. [23] 周青丽,许真源,张素妍,石安华,张顺贞.NOD样受体蛋白3炎症小体在非酒精性脂肪性肝炎中的作用.临床肝胆病杂志.2019.35(6):4. [24] Wan X,Xu C,Yu C,Li Y.Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH.Can J Gastroenterol Hepatol.2016.2016:6489012. [25] Torres S,Brol MJ,Magdaleno F,et al.The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.Front Mol Biosci.2021. 8:715765. [26] Stienstra R,van Diepen JA,Tack CJ,et al.Inflammasome is a central player in the induction of obesity and insulin resistance.Proc Natl Acad Sci U S A.2011.108(37):15324-9. [27] Dixon LJ,Flask CA,Papouchado BG,Feldstein AE,Nagy LE.Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis.PLoS One.2013.8(2):e56100. [28] Wree A,McGeough MD,Peña CA,et al.NLRP3 inflammasome activation is required for fibrosis development in NAFLD.J Mol Med(Berl).2014.92(10):1069-82. [29] Huang S,Wu Y,Zhao Z,et al.A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.Metabolism.2021.120:154797. [30] Swanson KV,Deng M,Ting JP.The NLRP3 inflammasome:molecular activation and regulation to therapeutics.Nat Rev Immunol. 2019.19(8):477-489. [31] Csak T,Ganz M,Pespisa J,Kodys K,Dolganiuc A,Szabo G.Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells.Hepatology.2011.54(1):133-44. [32] Knorr J,Wree A,Tacke F,Feldstein AE.The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.Semin Liver Dis. 2020.40(3):298-306. [33] Kuba M,Matsuzaka T,Matsumori R,et al.Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-)mouse model.Sci Rep.2015.5:17604. [34] Liu X,Zhang Z,Ruan J,et al.Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores.Nature.2016.535(7610):153-8. [35] Gaul S,Leszczynska A,Alegre F,et al.Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.J Hepatol.2021.74(1):156-167. [36] Wang Q,Ou Y,Hu G,et al.Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice.Br J Pharmacol.2020.177(8):1806-1821. [37] 俞建顺,陈芝芸.炎症小体与非酒精性脂肪性肝炎.医学研究杂志.2019.48(12):152-157. [38] He K,Zhu X,Liu Y,et al.Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.Oncotarget.2017.8(23):37657-37672. [39] Vande Walle L,Stowe IB,Šácha P,et al.MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.PLoS Biol.2019. 17(9):e3000354. [40] Wang L,Hauenstein AV.The NLRP3 inflammasome:Mechanism of action,role in disease and therapies.Mol Aspects Med.2020.76:100889. [41] Mridha AR,Wree A,Robertson A,et al.NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.J Hepatol.2017.66(5):1037-1046. [42] De Carvalho Ribeiro M,Szabo G.Role of the Inflammasome in Liver Disease.Annu Rev Pathol.2022.17:345-365. [43] Colak Y,Hasan B,Erkalma B,et al.Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target.Clin Res Hepatol Gastroenterol.2021.45(4):101710. [44] Beier JI,Banales JM.Pyroptosis:An inflammatory link between NAFLD and NASH with potential therapeutic implications.J Hepatol. 2018.68(4):643-645. [45] Ganz M,Csak T,Szabo G.High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.World J Gastroenterol.2014.20(26):8525-34. [46] 黄清宇,杜楚江,张雨竹,曹宏伟,郝慧芳.细胞焦亡研究进展.中国免疫学杂志.2020.36(02):245-250. [47] Broz P,Pelegrín P,Shao F.The gasdermins,a protein family executing cell death and inflammation.Nat Rev Immunol.2020.20(3):143-157. [48] Sharma BR,Kanneganti TD.NLRP3 inflammasome in cancer and metabolic diseases.Nat Immunol.2021.22(5):550-559. [49] 范祺,郭翼宁,张卫光.GSDMD调控非酒精性脂肪肝中细胞焦亡的研究进展.中国组织化学与细胞化学杂志.2019.28(02):174-178. [50] Khanova E,Wu R,Wang W,et al.Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology.2018.67(5):1737-1753. [51] Al Mamun A,Akter A,Hossain S,et al.Role of NLRP3 inflammasome in liver disease.J Dig Dis.2020.21(8):430-436. [52] 张文杰,孙迪阳,王培.炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制.药学实践杂志.2020.38(01):9-13+41. [53] Wen H,Gris D,Lei Y,et al.Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling.Nat Immunol. 2011.12(5):408-15. [54] Wree A,Eguchi A,McGeough MD,et al.NLRP3 inflammasome activation results in hepatocyte pyroptosis,liver inflammation,and fibrosis in mice.Hepatology.2014.59(3):898-910. [55] 邓涛,龚建平,何堃.NLRP3基因敲除对非酒精性脂肪性肝炎小鼠的影响.山东医药.2019.59(01):1-4. [56] 饶紫兰,陈聪杰,胡俊等.NOD样受体家族3基因敲除对改善非酒精性脂肪性肝炎小鼠肝损伤及脂代谢的影响.中国临床药理学杂志.2021.37(16):2217-2220. [57] Witek RP,Stone WC,Karaca FG,et al.Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.Hepatology.2009.50(5):1421-30. [58] Kim SH,Kim G,Han DH,et al.Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.Autophagy.2017. 13(10):1767-1781. [59] De Minicis S,Rychlicki C,Agostinelli L,et al.Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice.Hepatology.2014.59(5):1738-49. [60] Henao-Mejia J,Elinav E,Jin C,et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012.482(7384):179-85. [61] Luan J,Ju D.Inflammasome:A Double-Edged Sword in Liver Diseases.Front Immunol.2018.9:2201. [62] 刘言.S100A8介导的NLRP3炎症小体依赖性细胞焦亡在肝纤维化进程中的作用机制及临床价值研究,2023. [63] 张发君,马萍.NLRP3炎症小体与细胞焦亡相关研究进展.世界最新医学信息文摘.2017.17(38):33-34.

点击下载PDF